Real experience of brentuximab vedotin for cutaneous T cell lymphomas
Makaleler > Tam Makale · 2020
Yazarlar: Fatma KEKLİK KARADAĞ, A. Arslan, T. Pashayev, Nur SOYER, Fahri ŞAHİN, Filiz VURAL, Mahmut TÖBÜ, Güray SAYDAM
Hematology, Transfusion and Cell Therapy, Uluslararası, Scopus, 2020, cilt 42, ss 20-21
DOI: 10.1016/j.htct.2020.09.039
Özet
hematol transfus cell ther. 2 0 2 0;4 2(S 1):S17-S34 Results: Analysis of the data obtained has shown that, during the reporting period the average annual incidence of MPN was 1.84 per 100,000 inhabitants, including 2.1 for male and 1.64 for female.Analysis of incidence rates of MPN in relation to sex and age in the period under study revealed high rates in patients in groups 65-74 (8.3) and 55-64 (5.12 per 100 thousand years), respectively.According to the data obtained in the group of patients with MPN, the high annual average incidence rates are noted in PMF (1.09 in 2018) and PV (0.89 in 2016), the lowest for ET (0.7 in 2016) per 100,000 population, respectively.In comparing our data to those obtained for 1966-1971 and 1998-2004 periods, one may detect a statistically significant increase in the total incidence of PMF and PV (p < 0.001).Conclusion: Analysis of the incidence rate in MPNs adjusted for age and gender shown prevalence in group 65-74 (8.3) and in group 55-64 (5.13) per 100,000 inhabitants.The peak of incidence rate for both males and females was the age 65-74 and the male female incidence ratio in this age group was 11.3:6.2.The increasing incidence rate in MPNs in Armenia depends on the improvement of laboratory diagnosis.Thrombotic complications are observed in patients with MPN in 45.3% of cases.In most cases, thrombosis is the first clinical symptom of a myeloproliferative disease, which determines the need for the introduction into clinical practice of molecular genetic testing methods among patients with thrombosis, an increase in blood levels, splenomegaly for the early diagnosis of clonal hematopoiesis and the use of a targeted drug.